<DOC>
	<DOCNO>NCT02716090</DOCNO>
	<brief_summary>This study evaluate non-inferiority product Dalap Duo® compare Epiduo® medicine treat acne . Half participant receive Dalap Duo® , half receive Epiduo® .</brief_summary>
	<brief_title>Clinical Trial Phase III Assess Non-inferiority Dalap Duo® Product Compared Epiduo® Treatment Acne Vulgaris</brief_title>
	<detailed_description>The investigational product produce Aché evaluate trial cream gel , comprise 0.1 % adapalene 2.5 % benzoyl peroxide . It 's topical cream gel store laminated tube contain 30 gram . Of 376 research participant acne vulgaris participate study , 188 treat investigational product Cream Gel . The duration participant study one hundred twenty-four day , contemplate screen visit , randomization visit , four follow-up visit , final visit phone contact 30 day final visit . Of one hundred twenty fourth day study period , participant treat eighty four day . Regarding control group , active comparator Epiduo® , manufacture Galderma Laboratories , formulation compose 0.1 % adapalene 2.5 % benzoyl peroxide . This topical gel store laminated tube 30 gram . Of 376 research participant acne vulgaris participate study , 188 treat active comparator Epiduo® . The duration participant study one hundred twenty-four day , contemplate screen visit , randomization visit , four follow-up visit , final visit phone contact 30 day final visit . Of One hundred twenty fourth day study period , participant treat eighty four day .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene , Benzoyl Peroxide Drug Combination</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>1. female male Participant 2 . Age old equal 12 year ; 3 . 30100 noninflammatory facial lesion , except nose region ( comedo close open comedo degree 1 ) 20 50 inflammatory facial lesion , except nose region ( papule pustule degree 2 ) ; 4 . Ability understand consent participate clinical study , express signing consent form ; 5 . Search Participant willing use , entire period study drug , cosmetic / treatment acne , accord investigator , may influence study result , , limited , treatment oral topical retinoids . 1 . Any finding clinical observation ( clinical assessment / physical ) interpret investigator risk safety may interfere effectiveness treatment research participant clinical trial ; 2 . Any laboratory examination find investigator consider safety risk may interfere effectiveness treatment research participant clinical trial ; 3 . Known hypersensitivity drug component use study ; 4. female participant history polycystic ovary syndrome ( SteinLeventhal syndrome ) ; 5 . Women positive result urinary beta human chorionic gonadotropin gestation period breastfeeding ; 6 . Women reproductive age agree use acceptable contraception [ oral contraceptive , injectable contraceptive , intrauterine device ( IUD ) , hormonal implant , barrier method , hormonal patch tubal ligation ] ; surgically sterile ( bilateral oophorectomy hysterectomy ) sexual abstinence yet initiate sexual activity ; 7 . Person participate clinical trial protocol last twelve ( 12 ) month , unless investigator considers may direct benefit him/her ; 8 . Participant kinship second degree bond employee employee Sponsor Research Center ; 9 . Women menopausal postmenopausal period ; 10 . Any feature test area ( face ) accord investigator may influence result , example , BUT NOT LIMITED TO mole , tattoo , scar , irritated skin , scratch , cut excess hair ; 11 . Participants diagnose Diabetes Mellitus evaluation result test , define presence classic symptom diabetes mellitus assess visit V1 associate high level casual plasma glucose equal 200 mg / dL accord American Diabetes Association ( DIABETES CARE , VOLUME 33 , SUPPLEMENT 1 , JANUARY 2010 ) ; 12 . Presence dermatosis relate diabetes mellitus ( plantar ulcer , necrobiosis lipoid , annular granuloma , dermatophytosis , deep mycoses , bacterial infection , opportunistic infection ) ; 13. immune impairment ; 14 . Dermatological disease test area ( face ) : vitiligo , psoriasis , atopic dermatitis ; 15 . Participant use topical treatment acne 15 day precede screen visit ( V1 ) oral treatment acne 30 day precede screen visit ( V1 ) plan use study period ; 16 . Participant cyst lump face region ; 17 . Use medication / treatment contrary describe item 11.2. Protocol ; 18 . Other disease medication , accord investigator , would interfere directly result study jeopardize health participant .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>